Woodhouse

David J. Woodhouse, PhD

Chairman, Surrozen
Chief Executive Officer, NGM Biopharmaceuticals
Dr. David J. Woodhouse brings to Surrozen’s board more than 18 years of experience throughout the biopharmaceutical industry, as a scientist and with expertise in strategy, finance, and capital development for growing biotechnology companies. He currently serves as the Chief Executive Officer and a director at NGM Biopharmaceuticals. He previously served as NGM’s Chief Financial Officer for over three years. From 2002 to 2015, he was an investment banker at Goldman Sachs & Co. LLC, most recently as a Managing Director in the healthcare investment banking group and co-head of biotechnology investment banking. Earlier in his career, Dr. Woodhouse worked at Dynavax Technologies and also as a research assistant at Amgen, Inc. Dr. Woodhouse received a B.A. in pharmacology from the University of California, Santa Barbara, an M.B.A. from the Tuck School of Business at Dartmouth and a Ph.D. in molecular pharmacology from Stanford University School of Medicine.
Chairman of the Board
  • Member of the Audit Committee